IMU Biosciences
IMU Biosciences is a biotechnology company coupling high-resolution, systems-level immune profiling with proprietary AI analytics to build a detailed atlas of the human immune system across health and disease.
Its platform can identify and analyse over 2,000 immune cell subsets from blood samples, generating predictive signatures for disease monitoring.
Applications span immuno-oncology, transplantation, autoimmune disease, and cell therapy development.
IMU partners with pharmaceutical companies and is a key contributor to the MANIFEST immunotherapy research consortium.
Latest News
IMU Biosciences Partners with UK Biobank to Profile Immune Systems of 80,000 Participants
IMU Biosciences is partnering with UK Biobank, Waters Corporation and Ultima Genomics to generate multi-omic immune profiling data from an initial 80,000 UK Biobank blood samples, with the aim of expanding to all 500,000 participants. IMU will apply its HD Immunology platform and build foundational AI models for immunology, backed by a £1.57 million UK government Sovereign AI grant.
IMU Biosciences Licenses HD Immunology Platform to Eurofins Transplant Genomics
IMU Biosciences has signed a licensing agreement giving Eurofins Transplant Genomics exclusive access to its High Definition Immunology platform for transplant-related clinical development programmes. The deal puts IMU's high-throughput immune profiling into one of the largest post-transplant monitoring networks, targeting suboptimal immunosuppression as a driver of chronic rejection and premature graft loss.